Literature DB >> 21563904

Post-exposure therapy with human butyrylcholinesterase following percutaneous VX challenge in guinea pigs.

Helen Mumford1, Matthew E Price, David E Lenz, Douglas M Cerasoli.   

Abstract

CONTEXT: Human butyrylcholinesterase (huBuChE) has potential utility as a post-exposure therapy following percutaneous nerve agent poisoning as there is a slower absorption of agent by this route and hence a later onset of poisoning. METHODS. We used surgically implanted radiotelemetry devices to monitor heart rate, EEG, body temperature and locomotor activity in guinea pigs challenged with VX via the percutaneous route. RESULTS. Treatment with huBuChE (24.2 mg/kg, i.m.) at 30 or 120 min following percutaneous VX (~2.5 × LD(50)) protected 9 out of 10 animals from lethality. When i.m. huBuChE administration was delayed until the onset of observable signs of systemic cholinergic poisoning, only one out of six animals survived to 7 days. Survival increased to 50% when the same dose of huBuChE was given intravenously at the onset of signs of poisoning. This dose represents approximately 1/10th the stoichiometric equivalent of the dose of VX administered (0.74 mg/kg). Intramuscular administration of huBuChE (24.2 mg/kg) alone did not produce any changes in heart rate, brain electrical activity, temperature or locomotion compared to saline control. Survival following VX and huBuChE treatment was associated with minimal incapacitation and observable signs of poisoning, and the mitigation or prevention of detrimental physiological changes (e.g. seizure, bradycardia and hypothermia) observed in VX + saline-treated animals. At 7 days, cholinesterase activity in the erythrocytes and most brain areas of guinea pigs that received huBuChE at either 18 h prior to or 30 min following VX was not significantly different from that of naïve, weight-matched control animals. CONCLUSION. Percutaneous VX poisoning was successfully treated using post-exposure therapy with huBuChE bioscavenger. The opportunity for post-exposure treatment may have particular relevance in civilian settings, and this is a promising indication for the use of huBuChE.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21563904     DOI: 10.3109/15563650.2011.568944

Source DB:  PubMed          Journal:  Clin Toxicol (Phila)        ISSN: 1556-3650            Impact factor:   4.467


  5 in total

1.  Post-exposure therapy with recombinant human BuChE following percutaneous VX challenge in guinea-pigs.

Authors:  Helen Mumford; John K Troyer
Journal:  Toxicol Lett       Date:  2011-05-19       Impact factor: 4.372

2.  Catalytic detoxification of nerve agent and pesticide organophosphates by butyrylcholinesterase assisted with non-pyridinium oximes.

Authors:  Zoran Radić; Trevor Dale; Zrinka Kovarik; Suzana Berend; Edzna Garcia; Limin Zhang; Gabriel Amitai; Carol Green; Božica Radić; Brendan M Duggan; Dariush Ajami; Julius Rebek; Palmer Taylor
Journal:  Biochem J       Date:  2013-02-15       Impact factor: 3.857

3.  Three-dimensional brain-on-chip model using human iPSC-derived GABAergic neurons and astrocytes: Butyrylcholinesterase post-treatment for acute malathion exposure.

Authors:  Lumei Liu; Youngmi Koo; Teal Russell; Elaine Gay; Yan Li; Yeoheung Yun
Journal:  PLoS One       Date:  2020-03-12       Impact factor: 3.240

4.  Tuning Butyrylcholinesterase Inactivation and Reactivation by Polymer-Based Protein Engineering.

Authors:  Libin Zhang; Stefanie L Baker; Hironobu Murata; Nicholas Harris; Weihang Ji; Gabriel Amitai; Krzysztof Matyjaszewski; Alan J Russell
Journal:  Adv Sci (Weinh)       Date:  2019-11-13       Impact factor: 16.806

5.  Imidazole aldoximes effective in assisting butyrylcholinesterase catalysis of organophosphate detoxification.

Authors:  Rakesh K Sit; Valery V Fokin; Gabriel Amitai; K Barry Sharpless; Palmer Taylor; Zoran Radić
Journal:  J Med Chem       Date:  2014-02-07       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.